From Targeted Therapy to the ADC Era: Which Lung Cancer Patients Are Suitable for TROP2 ADC Therapy?

Learn how TROP2 antibody-drug conjugates (ADCs) are transforming lung cancer treatment, which patients may benefit, and the future prospects of this innovative precision therapy.

Top Stories

Understanding Breast Cancer Subtypes: Differences Between Luminal A, Luminal B, HER2-Positive, and Triple-Negative Breast Cancer

How Do ADCs Treat Lung Cancer? Which Patients May Benefit?

Latest Coverage

Perioperative Antibiotic Guidelines: Rational Drug Selection and Duration Control
Surgical Site Infection (SSI) is one of the most common complications during the perioperative period. It not only pr...

What Targeted Drugs Are Available for NTRK Fusion Brain Tumors? An Overview of Larotrectinib and Entrectinib Applications
With the advancement of precision medicine, brain tumor treatment has gradually shifted from traditional histological...

AI-Driven Drug Discovery: Top 5 Chinese AI Drug Discovery Companies
Over the past few years, the global AI drug discovery industry has experienced rapid financing, soaring valuations, a...

Opportunities and Challenges in Supplying Medicines to Emerging and Underserved Markets
Explore how underserved and emerging markets are becoming a new growth engine for the pharmaceutical industry, the op...

From Inhibition to Degradation: Why Is PROTAC Considered the Next Revolution in Drug Discovery?
Discover how PROTAC technology is transforming drug discovery by shifting from protein inhibition to targeted protein...

Mirdametinib vs Selumetinib: Which MEK Inhibitor Is Better for Neurofibromatosis Type 1 (NF1)?
Neurofibromatosis Type 1 (NF1) is a common autosomal dominant genetic disorder caused by mutations in the NF1 gene. I...

In-Depth Analysis

From Targeted Therapy to the ADC Era: Which Lung Cancer Patients Are Suitable for TROP2 ADC Therapy?

Understanding Breast Cancer Subtypes: Differences Between Luminal A, Luminal B, HER2-Positive, and Triple-Negative Breast Cancer

How Do ADCs Treat Lung Cancer? Which Patients May Benefit?

Perioperative Antibiotic Guidelines: Rational Drug Selection and Duration Control